文献速递中毒与环境急症消化、代谢与肾脏急症

海洛因过量后非药用芬太尼暴露的自我识别

Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose.
PubMed 文献 · Clin Toxicol (Phila) · 2017-07-06
一句话结论海洛因过量需纳洛酮解毒的急诊患者中,仅55%能自我识别海洛因中掺有芬太尼,尿检证实96.7%存在芬太尼暴露。

本研究为横断面研究,纳入30例因海洛因过量需纳洛酮解毒的成人急诊患者,比较患者自我识别非药用芬太尼暴露与确证性尿液药物检测的一致性。尿液用液相色谱-四极杆飞行时间质谱分析,检测芬太尼、海洛因代谢物及其他隐匿性阿片类。结果显示尿芬太尼检出率96.7%、去甲芬太尼93.3%、海洛因或其代谢物93.3%,乙酰芬太尼30%、U-47700 6.7%;仅16例(55%)自我识别海洛因中含芬太尼。作者认为海洛因使用者无法准确识别掺入的非药用芬太尼。

要点

  • 30例海洛因过量需纳洛酮的急诊成人中,尿检芬太尼检出率96.7%、去甲芬太尼93.3%,海洛因或其代谢物93.3%。
  • 仅16例(55%)自我识别海洛因中含芬太尼,患者对芬太尼掺入的定性识别能力不一致。
  • 尿检还检出意外隐匿性阿片类:乙酰芬太尼9例(30%)、U-47700 2例(6.7%)。
  • 所有尿液药物筛查均检出纳洛酮;12例(40%)报告同时使用可卡因,20例(67%)报告近期戒断。

适用人群与场景

  • 成人急诊患者,因海洛因过量就诊且需要纳洛酮解毒。

研究设计与关键结果

  • 横断面研究,纳入30例因海洛因过量需纳洛酮解毒的成人急诊患者,参与者提供尿液样本,用液相色谱-四极杆飞行时间质谱检测芬太尼、海洛因代谢物、其他隐匿性阿片类、常用药物和滥用药物。
  • 尿检结果:纳洛酮所有样本均检出;海洛因或其代谢物检出率93.3%;芬太尼检出率96.7%;去甲芬太尼检出率93.3%;乙酰芬太尼9例(30%);U-47700 2例(6.7%)。
  • 自我识别:16例(55%)自我识别海洛因中含芬太尼,患者对海洛因中芬太尼的定性识别能力不一致。
  • 其他报告:10例(33%)既往从未因过量需要纳洛酮;20例(67%)报告近期戒断;12例(40%)报告同时使用可卡因。

证据类型、等级与局限

  • 证据类型:横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,因海洛因过量需纳洛酮解毒而就诊急诊的海洛因使用者无法准确识别海洛因中是否存在非药用芬太尼。
  • 作者指出,先进药物检测方法在本研究患者中检出芬太尼暴露达96.7%,并检出意外的隐匿性阿片类(如乙酰芬太尼和U-47700)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare user self-identification of nonpharmaceutical fentanyl exposure with confirmatory urine drug testing in emergency department (ED) patients presenting after heroin overdose.

METHODS: This was a cross-sectional study of adult ED patients who presented after a heroin overdose requiring naloxone administration. Participants provided verbal consent after which they were asked a series of questions regarding their knowledge, attitudes and beliefs toward heroin and nonpharmaceutical fentanyl. Participants also provided urine samples, which were analyzed using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry to identify the presence of fentanyl, heroin metabolites, other clandestine opioids, common pharmaceuticals and drugs of abuse.

RESULTS: Thirty participants were enrolled in the study period. Ten participants (33%) had never required naloxone for an overdose in the past, 20 participants (67%) reported recent abstinence, and 12 participants (40%) reported concomitant cocaine use. Naloxone was detected in all urine drug screens. Heroin or its metabolites were detected in almost all samples (93.3%), as were fentanyl (96.7%) and its metabolite, norfentanyl (93.3%). Acetylfentanyl was identified in nine samples (30%) while U-47700 was present in two samples (6.7%). Sixteen participants self-identified fentanyl in their heroin (sensitivity 55%); participants were inconsistent in their qualitative ability to identify fentanyl in heroin.

CONCLUSIONS: Heroin users presenting to the ED after heroin overdose requiring naloxone are unable to accurately identify the presence of nonpharmaceutical fentanyl in heroin. Additionally, cutting edge drug testing methodologies identified fentanyl exposures in 96.7% of our patients, as well as unexpected clandestine opioids (like acetylfentanyl and U-47700).

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Griswold MK, Chai PR, Krotulski AJ, et al. Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose. Clin Toxicol (Phila). 2017. PMID: 28681615. doi:10.1080/15563650.2017.1339889

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。